1. Effect of Daily Vitamin D Supplementation on Risk of Upper Respiratory Infection in Older Adults: A Randomized Controlled Trial.
- Author
-
Camargo CA Jr, Schaumberg DA, Friedenberg G, Dushkes R, Glynn RJ, Gold DR, Mora S, Lee IM, Buring JE, and Manson JE
- Subjects
- Humans, Male, Female, Aged, Double-Blind Method, Middle Aged, Vitamin D Deficiency drug therapy, Vitamin D Deficiency complications, Fatty Acids, Omega-3 administration & dosage, Fatty Acids, Omega-3 therapeutic use, Respiratory Tract Infections prevention & control, Respiratory Tract Infections epidemiology, Dietary Supplements, Vitamin D blood, Vitamin D analogs & derivatives, Vitamin D administration & dosage
- Abstract
Background: Among individuals with vitamin D deficiency, daily vitamin D supplementation appears to lower risk of acute respiratory infection. However, recent trials, in different populations and using different regimens, have yielded null results. We investigated the effect of daily vitamin D supplementation (vs placebo) on risk of upper respiratory infection (URI) in older adults., Methods: The VITamin D and OmegA-3 TriaL (VITAL) is a randomized, double-blind, placebo-controlled trial of supplemental vitamin D and/or omega-3 fatty acids in generally healthy men (age ≥50 years) and women (age ≥55 years). This prespecified analysis focuses on vitamin D3 (2000 IU/day) versus placebo in the 15 804 (61%) participants with baseline serum total 25-hydroxyvitamin D level. The primary outcome was self-report of a recent URI at 1-year follow-up., Results: Participants had a mean age of 68 years and 51% were women; 76% were non-Hispanic White, 16% Black, and 8% other race/ethnicity. The mean 25-hydroxyvitamin D level at baseline was 31 (standard deviation, 10) ng/mL, with <12 ng/mL in 2.4%. The overall effect of vitamin D supplementation on recent URI was nonsignificant (odds ratio [OR], 0.96 [95% confidence interval {CI}, .86-1.06]). In the prespecified subgroup of primary interest (<12 ng/mL and denied taking concurrent vitamin D), which had only 255 participants, vitamin D supplementation was nonsignificant (OR, 0.60 [95% CI, .28-1.30]). Statistical power to assess effect modification in other subgroups was limited., Conclusions: In older adults not selected for vitamin D deficiency, supplemental vitamin D did not lower URI risk overall. Whether effects differ in subgroups requires further study. Clinical Trials Registration. NCT01169259., Competing Interests: Potential conflicts of interest. C. A. C. received support for the present manuscript from the NIH, Pharmavite, Pronova BioPharma/BASF, and Quest Diagnostics paid to their institution. R. J. G. reported receipt of grants from Amarin, Kowa, Novartis, and Pfizer; participation on a data safety monitoring board or advisory board for National Heart, Lung, and Blood Institute trials of blood disorders, HI-PRO Trial of venous thromboembolism prevention, and the CANARY trial of cannabidiol. D. R. G. has received grants or contracts from the NIH. S. M. reports consulting for Quest Diagnostics and Pfizer. J. E. B. reports that her spouse is a member of the scientific advisory board of Pharmavite, which provided the vitamin D pills and packaging for the trial. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed., (© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF